FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $58,086 | +85.1% | 15,531 | +4.9% | 0.01% | +57.1% |
| Q3 2023 | $31,389 | -45.6% | 14,806 | +22.1% | 0.01% | -41.7% |
| Q2 2023 | $57,729 | -7.9% | 12,128 | +10.3% | 0.01% | -33.3% |
| Q1 2023 | $62,677 | -43.1% | 10,996 | +0.8% | 0.02% | -83.2% |
| Q4 2022 | $110,122 | -56.0% | 10,914 | -2.1% | 0.11% | -53.5% |
| Q3 2022 | $250,000 | -12.0% | 11,146 | -2.7% | 0.23% | +6.5% |
| Q2 2022 | $284,000 | -42.4% | 11,452 | -9.9% | 0.22% | -6.9% |
| Q1 2022 | $493,000 | -42.2% | 12,708 | -12.8% | 0.23% | -25.4% |
| Q4 2021 | $853,000 | – | 14,577 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |